The 10 most recent market catalysts affecting $ALVO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 75
Alvotech shares are trading higher after Barclays upgraded the stock from Underweight to Overweight rating and raised its price target from $4 to $8.
The upgrade from Underweight to Overweight by a major investment bank like Barclays, coupled with a doubling of the price target, is a significant positive catalyst for Alvotech. T…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 65
Barclays Upgrades Alvotech to Overweight, Raises Price Target to $8
Barclays analyst Glen Santangelo upgraded Alvotech (ALVO) from Underweight to Overweight and significantly raised the price target from $4 to $8. This move indicates a substantial …
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
Alvotech Announced That The U.S. Food And Drug Administration Has Accepted For Review A Biologics License Application For AVT80, A Proposed Interchangeable Biosimilar To Entyvio (Vedolizumab) Prefilled Syringe And Autoinjector For Subcutaneous Administration
This headline is a significant corporate catalyst for Alvotech, as the FDA's acceptance of the BLA for AVT80 brings them closer to commercializing a biosimilar to Entyvio. The 'int…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 75
Alvotech shares are trading higher after B of A Securities initiated coverage on the stock with a Buy rating and announced a $7 price target.
This headline represents a significant corporate catalyst for Alvotech. Analyst initiations, especially from major institutions like BofA Securities, often provide a strong endorse…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 65
B of A Securities Initiates Coverage On Alvotech with Buy Rating, Announces Price Target of $7
B of A Securities initiating coverage on Alvotech with a 'Buy' rating and a $7 price target is a positive development for the company. Analyst coverage, especially from a major ins…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 75
Alvotech Announces $150M Licensing And Commercialization Agreement With Lotus Pharmaceutical Plus Milestone Payments For Durvalumab, Emicizumab Biosimilars In U.S. And Eight Asian Markets
This headline represents a significant positive catalyst for Alvotech (ALVO) as it secures a substantial upfront payment and future milestone payments, validating its biosimilar pi…
Aug 19, 2026
Corporate Catalyst
Bearish
Impact 95
Alvotech Q2 EPS $(0.17) Misses $(0.04) Estimate, Sales $106.000M Miss $111.010M Estimate
Alvotech's Q2 earnings per share of $(0.17) missed the consensus estimate of $(0.04) by a substantial 325%, and sales of $106 million missed the $111.01 million estimate by 4.51%. …
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 55
Evercore ISI Group Initiates Coverage On Alvotech with Outperform Rating
Evercore ISI Group, a well-known investment bank, has started covering Alvotech with an 'Outperform' rating. This is significant because new analyst coverage, especially with a pos…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Alvotech shares are trading higher. The company announced the FDA has closed its inspection of its Reykjavik manufacturing facility, classifying the site as Voluntary Action Indicated.
This headline represents a significant positive corporate catalyst for Alvotech. The FDA's VAI classification indicates that while some observations were made during the inspection…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 65
Alvotech Says FDA Closes Inspection Of Manufacturing Facility In Reykjavik, Iceland; FDA Confirms Inspection Classification Of Manufacturing Site Is Voluntary Action Indicated
Alvotech announced that the FDA has completed its inspection of their manufacturing facility in Reykjavik, Iceland, and classified the outcome as 'Voluntary Action Indicated' (VAI)…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.